Primary choice of estrogen and progestogen as components for HRT: a clinical pharmacological view

References

• Concato J, Shah N, Horwitz RI. Randomized, controlled trials, observational studies, and the hierarchy of research designs. N Engl J Med. 2000;342(25):1887–1892.
   PubMed Web of Science ®Google Scholar
• Benson K, Hartz AJ. A comparison of observational studies and randomized, controlled trials. N Engl J Med. 2000;342(25):1878–1886.
   PubMed Web of Science ®Google Scholar
• Rossouw JE, Anderson GL, Prentice RL, et al. Risks and benefits of estrogen plus progestin in healthy postmenopausal women: principal results from the Women’s Health Initiative randomized controlled trial. JAMA. 2002;288(3):321–333.
   PubMed Web of Science ®Google Scholar
• Anderson GL, Limacher M, Assaf AR, et al. Women’s health initiative steering committee. Effects of conjugated equine estrogen in postmenopausal women with hysterectomy: the women’s health initiative randomized controlled trial. JAMA. 2004;291:701–712.
   Web of Science ®Google Scholar
• Genazzani AR, Monteleone P, Giannini A, et al. Hormone therapy in the postmenopausal years: considering benefits and risks in clinical practice. Hum Reprod Update. 2021;27(6):1115–1150.
   PubMed Web of Science ®Google Scholar
• L'Hermite M, Simoncini T, Fuller S, et al. Could transdermal estradiol + progesterone be a safer postmenopausal HRT? A review. Maturitas. 2008;60(3–4):185–201.
   PubMed Web of Science ®Google Scholar
• Langer RD, Hodis NN, Lobo RA, et al. Hormone replacement therapy – where are we now. Climacteric. 2021;24(1):3–10.
   PubMed Web of Science ®Google Scholar
• Dey M, Lyttle RC, Pickar JH. Recent insights into varying activity of estrogens. Maturitas. 2000;34:S25–S33.
   PubMed Web of Science ®Google Scholar
• Stanczyk F. Estrogens used for replacement therapy in postmenopausal women. Gynecol Endocrinol. 2001;15(Suppl.4):17–25.
   Google Scholar
• Lippert TH, Seeger H, Mueck AO. Pharmacology and toxicology of different estrogens. Gynecol Endocrinol. 2001;15(Suppl.4):26–33.
   Google Scholar
• Parfit K. Martindale. The complete drug reference. London. Pharmaceutical Press (35th edition); 2005. pp. 1543–1544.
   Google Scholar
• Bhavnani BR, Cecutti A, Dey MS. Effect in postmenopausal women of Delta-8-estrone sulfate: a novel estrogen component of Premarin. J Soc Gynecol Investig. 1997;4(Suppl.1):Abstract No.392.
   Google Scholar
• Bhavnani BR. Pharmacokinetics and pharmacodynamics of conjugated equine estrogens: chemistry and metabolism. Proc Soc Exp Biol Med. 1998;217(1):6–16.
   PubMed Web of Science ®Google Scholar
• Kuhl H. Pharmacology of estrogens and progestogens: influence of different routes of administration. Climacteric. 2005;8(Suppl 1):3–63.
   PubMed Web of Science ®Google Scholar
• Gruber DM, Huber JC. Conjugated estrogens – the natural SERMs. Gynecol Endocrinol. 1999;13(Suppl.6):9–12.
   PubMedGoogle Scholar
• Chlebowski RT, Anderson GL, Aragaki AK, et al. Association of menopausal hormone therapy with breast cancer incidence and mortality during long-term follow-up of the Women’s Health Initiative Randomized Clinical Trials. JAMA. 2020;324(4):369–380.
   PubMed Web of Science ®Google Scholar
• Schierbeck LL, Rejnmark L, Tofteng CL, et al. Effect of hormone replacement therapy on cardiovascular events in recently postmenopausal women: randomised trial. BMJ. 2012;345:e6409.
   PubMed Web of Science ®Google Scholar
• Beral V (for collaborative group on hormonal factors in breast cancer): type and timing of hormone therapy and breast cancer risk: individual participant Meta-analysis of the worldwide epidemiological evidence. Lancet. 2019;2019:3941159–3941168.
   Google Scholar
• Jordan VC. The new biology of estrogen-induced apoptosis applied to treat and prevent breast cancer. Endocr Relat Cancer. 2015;22(1):R1–31.
   PubMed Web of Science ®Google Scholar
• Mueck AO, Seeger H. Estrogen as new option for prevention and treatment of breast cancer – does this need a "time-gap"? Climacteric. 2015;18(4):444–447.
   PubMed Web of Science ®Google Scholar
• Baber RJ, Panay N, Fenton A. 2016 IMS recommendations on women’s midlife health and menopause hormone therapy. Climacteric. 2016;19(2):109–150.
   PubMed Web of Science ®Google Scholar
• Mueck AO, Römer T. Choice of progestogen for endometrial protection in combination with transdermal estradiol in menopausal women. Horm Mol Biol Clin Investig. 2018;37(2):33.
   Web of Science ®Google Scholar
• Whitehead MI, Townsend PT, Pryse-Davis J, et al. Effects of estrogens and progestins on the biochemistry and morphology of the postmenopausal endometrium. N Engl J Med. 1981;305(27):1599–1605.
   PubMed Web of Science ®Google Scholar
• Whitehead MI, Townsend PT, Ryder T, et al. Effects of various types and dosages of progestogens on the postmenopausal endometrium. J Reprod Med. 1982;27(8 Suppl):539–548.
   PubMed Web of Science ®Google Scholar
• Gibbons WE, Moyer DLO, Lobo RA, et al. Biochemical and histologic effects of sequential estrogen/progestin therapy on the endometrium of postmenopausal women. Am J Obstet Gynecol. 1986;154(2):456–461.
   PubMed Web of Science ®Google Scholar
• Song JY, Fraser IS. Effects of progestogens on human endometrium. Obstet Gynecol Surv. 1995;50(5):385–394.
   PubMedGoogle Scholar
• Oettel M, Bervoas-Martin S, Elger W. A 19-norprogestin without a 17alpha-ethinyl-group. Dienogest from a pharmacodynamic point of view. Drugs Today. 1995;1995:517–536.
   Google Scholar
• Schindler AE, Campagnoli C, Druckmann R, et al. Classification and pharmacology of progestins. Maturitas. 2003;46:7–S16.
   PubMed Web of Science ®Google Scholar
• Oettel M, Carol W, Elger W, et al. A19-norprogestin without 17alpha-ethinyl-group: Dienogest from a pharmacokinetic point of view. Drugs Today. 1995;1995:499–516.
   Google Scholar
• Oettel M, Breitbarth E, Elger W, et al. The pharmacological profile of dienogest. Eur J Contacept Reprod Health Care. 1998;3:1–12.
   PubMedGoogle Scholar
• Harada T, Taniguchi F. Dienogest: a new therapeutic agent for the treatment of endometriosis. Womens Health. 2010;6(1):27–35.
   Google Scholar
• Johannisson E, Holinka CF, Arrenbrecht S. Transdermal sequential and continuous hormone replacement regiments with estradiol and norethisterone acetate in postmenopausal women: effects on the endometrium. Int J Fertil. 1997;42(Suppl.2):388–398.
   Google Scholar
• Oosterbaan HP, van Buuren A, Schram JHN, et al. The effects of continuous combined transdermal oestrogen-progestogen treatment on bleeding patterns and the endometrium in postmenopausal women. Maturitas. 1995;21(3):211–219.
   PubMed Web of Science ®Google Scholar
• Mueck AO, Bohnenstengel FI, Römer T. First low-dose combi-patch releasing 0.025 mg estradiol and 0.125 mg norethisterone acetate daily: endometrial safety, amenorrhoea rate and tolerability. Climacteric. 2005;8(Suppl.2):191–192.
   Google Scholar
• Samsioe G, Dvorak V, Genazzani AR, et al. One-year endometrial safety evaluation of a continuous combined transdermal matrix patch delivering low-dose estradiol-norethisterone acetate (NETA) in postmenopausal women. Maturitas. 2007;57(2):171–170.
   PubMed Web of Science ®Google Scholar
• Gräser T, Müller A, Mellinger U, et al. Continuous combined treatment of the menopause with combinations of oestradiol valerate and dienogest – a dose-ranging study. Maturitas. 2000;35(3):253–261.
   PubMed Web of Science ®Google Scholar
• Gräser T, Koytchev R, Müller A, et al. Comparison of the efficacy and endometrial safety of two estradiol valerate/dienogest combinations and kliogest for continuous combined hormone replacement therapy in postmenopausal women. Climacteric. 2000;3(2):109–118.
   PubMedGoogle Scholar
• Sasagawa S, Shimizu Y, Kami H, et al. Dienogest is a selective progesterone receptor agonist in transactivation analysis with potent oral endometrial activity due to its efficient pharmacokinetic profile. Steroids. 2008;73(2):222–231.
   PubMed Web of Science ®Google Scholar
• Mueck AO. Dienogest: an oral progestogen for the treatment of endometriosis. Expert Rev Obstet Gynecol. 2011;6(1):5–15.
   Google Scholar
• Gambrell RD, Jr Massey FM, Castaneda TA, et al. Use of the progestogen challenge test to reduce the risk of endometrial cancer. Obstet Gynecol. 1980;55(6):732–738.
   PubMed Web of Science ®Google Scholar
• Gambrell R. Use of progestogen therapy. Am J Obstet Gynecol. 1987;156(5):1304–1313.
   PubMed Web of Science ®Google Scholar
• el-Maraghy MA, el-Badawy N, Wafa GA, et al. Progesterone challenge test in postmenopausal women at high risk. Maturitas. 1994;19(1):53–57.
   PubMed Web of Science ®Google Scholar
• Bortoletto CC, Baracat EC, Gonçalves WJ, et al. Transvaginal ultrasonography and the progestogen challenge test in postmenopausal endometrial evaluation. Int J Gynaecol Obstet. 1997;58(3):293–298.
   PubMed Web of Science ®Google Scholar
• Schlaff WD, Coddington CC. Use of the progestin challenge test in diagnosing amenorrhea: the time has come to say goodbye. Fertil Steril. 2020;113(1):51–52.
   PubMed Web of Science ®Google Scholar
• Ruan X, Mueck AO. Impact of smoking on estrogenic efficacy. Climacteric. 2015;18(1):38–46.
   PubMed Web of Science ®Google Scholar
• Rabe T, Mueck AO, Deuringer FU, et al. Spacing-out of progestin-efficacy, tolerability and compliance of two regimens for hormonal replacement in the late postmenopause. Gynecol Endocrinol. 1997;11(6):383–392.
   PubMed Web of Science ®Google Scholar
• Mueck AO. Postmenopausal hormone replacement therapy and cardiovascular disease: the value of transdermal estradiol and micronized progesterone. Climacteric. 2012;15(Suppl 1):11–17.
   PubMedGoogle Scholar
• L’Hermite M. Bioidentical menopausal hormone therapy: registered hormones (non-oral estradiol ± progesterone) are optimal. Climacteric. 2017;20(4):331–338.
   PubMed Web of Science ®Google Scholar
• Stute P, Neulen J, Wildt L. The impact of micronized progesterone on the endometrium: a systematic review. Climacteric. 2016;19(4):316–328.
   PubMed Web of Science ®Google Scholar
• Gompel A. Progesterone, progestins and the endometrium in perimenopause and in menopausal hormone therapy. Climacteric. 2018;21:321–325.
   PubMed Web of Science ®Google Scholar
• Writing group for PEPI trial. Effects of hormone replacement therapy on endometrial histology in postmenopausal women. JAMA. 1996;275:370–375.
   PubMed Web of Science ®Google Scholar
• Bijuva TM. Estradiol and progesterone capsules, for oral use. Prescribing information. Boca Raton, FL: Therapeutics MD; 2018.
   Google Scholar
• Lobo RA, Archer DF, Kagan R, et al. A 17b-estradiol-progesterone oral capsule for vasomotor symptoms in postmenopausal women: a randomized controlled trial. Obstet Gynecol. 2018;132(1):161–170.
   PubMed Web of Science ®Google Scholar
• Lobo RA, Kaunitz AM, Santoro N, et al. Metabolic and cardiovascular effects of TX-001HR in menopausal women with vasomotor symptoms. Climacteric. 2019;22(6):610–617.
   PubMed Web of Science ®Google Scholar
• Mueck AO, Ruan X. Will estradiol/progesterone capsules for oral use become the best choice for menopausal hormone therapy? EDITORIAL. Climacteric. 2019;22(6):535–553.
   PubMed Web of Science ®Google Scholar
• Ruan X, Mueck AO. Systemic progesterone therapy-oral, vaginal, injections and even transdermal? Maturitas. 2014;79(3):248–255.
   PubMed Web of Science ®Google Scholar
• Ruan X, Mueck AO. Choice of progestogen for HRT in menopausal women: main issue breast cancer risk. Horm Mol Biol Clin Investig. 2018;37(1):19.
   Web of Science ®Google Scholar
• Fournier A, Berrino F, Clavel-Chapelon F. Unequal risks for breast cancer associated with different hormone replacement therapies: results from the E3N cohort study. Breast Cancer Res Treat. 2008;107(1):103–111.
   PubMed Web of Science ®Google Scholar
• Cordina-Duverger E, Truong T, Anger A, et al. Risk of breast cancer by type of menopausal hormone therapy: a case-control study among post-menopausal women in France. PLoS One. 2013;8(11):e78016–9.
   PubMed Web of Science ®Google Scholar
• Ruan X, Zhang Y, Mueck AO, et al. Increased expression of progesterone receptor membrane component 1 is associated with aggressive phenotype and poor prognosis in ER-positive and negative breast cancer. Menopause. 2017;24(2):203–209.
   PubMed Web of Science ®Google Scholar
• Ruan X, Cai G, Wei Y, et al. Association of circulating progesterone receptor membrane component-1 (PGRMC1) with breast tumor characteristics and comparison with known tumor markers. Menopause. 2020;27(2):183–193.
   PubMed Web of Science ®Google Scholar
• Neubauer H, Ma Q, Zhou J, et al. Possible role of PGRMC1 in breast cancer development. Climacteric. 2013;16(5):509–513.
   PubMed Web of Science ®Google Scholar
• Ruan X, Gu M, Cai G, et al. Progestogens and PGRMC1-dependent breast cancer tumor growth: an in-vitro and xenograft study. Maturitas. 2019;123:1–8.
   PubMed Web of Science ®Google Scholar
• Zhang L, Ruan X, Gu M, et al. E2 + norethisterone promotes the PI3K-AKT pathway via PGRMC1 to induce breast cancer cell proliferation. Climacteric. 2022;25:Epub ahead of print.
   PubMedGoogle Scholar
• Stanczyk FZ. Editorial. Can the increase in breast cancer observed in the estrogen plus progestin arm of the women’s health initiative trial be explained by progesterone receptor membrane component 1? Menopause. 2011;18(8):833–834.
   PubMed Web of Science ®Google Scholar
• Mueck AO, H, Seeger H. Progestogens and target tissues: vascular systems. Maturitas. 2009;62(4):356–361.
   PubMed Web of Science ®Google Scholar
• Mueck AO, Ruan X. Oral contraception for women of Middle age. Maturitas. 2015;82(3):266–270.
   PubMed Web of Science ®Google Scholar